Researchers at Columbia and Drexel universities have published the first high-resolution 3D structure of PfATP4, an essential sodium pump in the Plasmodium falciparum malaria parasite, alongside a newly discovered binding protein named PfABP. This breakthrough reveals critical vulnerabilities that could transform next-generation anti-malarial drug development against increasingly drug-resistant strains.
Global public health efforts against malaria face a compounding threat: the targeted parasite is steadily evolving resistance to current therapeutics. As progress stalls, researchers are racing to decode the fundamental biology of the pathogen to design more durable interventions.
In Plain English: The Clinical Takeaway
- Targeting the Parasite’s Pump: The study focuses on PfATP4, a specialized sodium pump that the malaria parasite relies on to survive.
- A New Vulnerability: Using advanced imaging, scientists discovered a previously unknown partner protein called PfABP that stabilizes the pump. Loss of this partner causes the pump to break down and kills the parasite.
- Beating Drug Resistance: Because the newly mapped binding protein appears less prone to mutations than the pump itself, it represents a target for drugs that parasites may find harder to evade.
Unlocking the 3D Architecture of PfATP4
For years, efforts to map the atomic structure of PfATP4 followed conventional structural biology methods. Typically, researchers insert a pathogen gene into yeast or bacterial cells, culture them in large batches, and image the harvested proteins using cryo-electron microscopy. However, expressing genes from Plasmodium falciparum in non-natural host cells frequently fails.
To overcome this, Chi-Min Ho pioneered specialized techniques allowing investigators to obtain high-resolution 3D structures of proteins isolated directly from parasite-infected blood cells. Utilizing the resources of the Columbia Electron Microscopy Center, the research team successfully visualized the endogenous PfATP4 sodium pump in its native cellular milieu. The resulting findings were published on October 20 in Nature Communications under the title “Endogenous structure of antimalarial target PfATP4 reveals an apicomplexan-specific P-1 type ATPase modulator” (Haile et al., 2025, Nat Commun 16:9092).
“Every year, malaria parasites adapt to outsmart our medicines. With the structure of PfATP4 now in hand and the discovery of this unknown partner, we have identified vulnerabilities that can be exploited for new therapies,” notes Chi-Min Ho, co-senior author and assistant professor of microbiology and immunology at the Columbia University Vagelos College of Physicians and Surgeons.
This structural blueprint maps precisely where clinically relevant drug resistance mutations occur. According to Akhil Vaidya, co-senior author and professor of microbiology and immunology at the Drexel University College of Medicine, “The findings provide a blueprint for next-generation drug discovery, offering ways to design molecules that target PfATP4.”
Discovery of the PfATP4 Binding Protein (PfABP)
Beyond mapping the pump itself, the high-resolution imaging revealed an unexpected macromolecular partner bound directly to PfATP4. Designated as the PfATP4 Binding Protein (PfABP), this regulatory molecule is essential for stabilizing the pump’s function and ensuring parasite survival.
“We found that loss of PfABP led to the rapid degradation of the PfATP4 sodium pump and death of the parasite,” explains co-first author Meseret Haile, a PhD student in the Microbiology, Immunology, and Infection program at Columbia’s Vagelos College of Physicians and Surgeons. Because PfABP appears less prone to mutations, drugs that target it may be harder for parasites to evade.
| Target Component | Biological Function | Implication for Drug Development |
|---|---|---|
| PfATP4 | Essential sodium pump. | Proven drug target, though parasites have rapidly developed resistance to experimental PfATP4 inhibitors. |
| PfABP (PfATP4 Binding Protein) | Newly discovered regulatory partner stabilizing the PfATP4 pump. | Essential for survival and appears less prone to mutations, offering a more durable therapeutic target. |
Funding Transparency and Global Health Impact
Contraindications & When to Consult a Doctor
This study represents early-stage foundational structural biology and molecular discovery; it does not constitute an approved treatment, clinical trial intervention, or medical advice for patients currently experiencing symptoms. Individuals traveling to malaria-endemic regions must continue to rely on established chemoprophylaxis and vector-control protocols prescribed by qualified healthcare providers. If you develop a fever, chills, headaches, or flu-like symptoms after visiting an area where malaria is transmitted, seek immediate medical evaluation and diagnostic blood testing at a certified clinical facility.
References
- Haile, M., et al. (2025). Endogenous structure of antimalarial target PfATP4 reveals an apicomplexan-specific P-1 type ATPase modulator. Nature Communications, 16, 9092.
Disclaimer: This article is for informational and educational purposes only and does not substitute for professional medical guidance, diagnosis, or treatment.
Related reading
- Study Links Late-Year Birth to Left-Handedness in Boys
- bNAbs Delay HIV Viral Rebound in RIO Trial: Phase 2 Results
- Did Venus Swallow Its Moon? New Astrophysics Study Reveals Shocking Theory (newsy-today.com)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)
